Low expression of fragile histidine triad gene correlates with high proliferation in head and neck squamous cell carcinoma

被引:19
作者
Mineta, H
Miura, K
Takebayashi, S
Misawa, K
Ueda, Y
Suzuki, I
Ito, M
Wennerberg, J
机构
[1] Hamamatsu Univ Sch Med, Dept Otolaryngol, Hamamatsu, Shizuoka 4313192, Japan
[2] Univ Lund Hosp, Dept Otorhinolaryngol Head & Neck Surg, S-22185 Lund, Sweden
[3] Hamamatsu Univ Hosp, Div Pathol, Hamamatsu, Shizuoka 4313192, Japan
关键词
fragile histidine triad (FHIT) gene; head and neck cancer; immunohistochemistry; Ki-67; expression;
D O I
10.1016/S1368-8375(02)00022-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Frequent loss of heterozygosity in head and neck squamous cell carcinoma (HNSCC) has been found in several chromosomal regions such as 3p, 9p, 11q, 13q and 17p. Fragile histidine triad (FHIT) gene is located at 3p14.2 encompassing a common fragile site, and is identified as a tumor suppressor gene. We examined 57 patients with HNSCC using immunohistochemistry, western blot, and reverse transcriptase polymerase chain reaction. The association between FHIT expression and clinicopathologic characteristics including p53 and Ki-67 expressions was analyzed. Immunohistochemical analysis revealed 30 patients (53%) of low FHIT expression and 27 patients (47%) of high FHIT expression. Low FHIT expression significantly correlated with high Ki-67 expression, indicating that tumor cells with low FHIT expression can proliferate aggressively. No correlation was found between FHIT expression and clinical characteristics including age, gender, tumor size, lymph node status, stage grouping, histologic grade, p53 expression, and prognosis. FHIT alteration may play an important role in cancer development of HNSCC, however it did not contribute to the prognosis. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:56 / 63
页数:8
相关论文
共 37 条
  • [1] AHSEE KW, 1994, CANCER RES, V54, P1617
  • [2] Loss of FHIT expression in transitional cell carcinoma of the urinary bladder
    Baffa, R
    Gomella, LG
    Vecchione, A
    Bassi, P
    Mimori, K
    Sedor, J
    Calviello, CM
    Gardiman, M
    Minimo, C
    Strup, SE
    McCue, PA
    Kovatich, AJ
    Pagano, F
    Huebner, K
    Croce, CM
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (02) : 419 - 424
  • [3] Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5'''-P-1,P-3-triphosphate hydrolase
    Barnes, LD
    Garrison, PN
    Siprashvili, Z
    Guranowski, A
    Robinson, AK
    Ingram, SW
    Croce, CM
    Ohta, M
    Huebner, F
    [J]. BIOCHEMISTRY, 1996, 35 (36) : 11529 - 11535
  • [4] Bieche I, 1998, GENE CHROMOSOME CANC, V23, P292, DOI 10.1002/(SICI)1098-2264(199812)23:4<292::AID-GCC3>3.3.CO
  • [5] 2-5
  • [6] Burke L, 1998, CANCER RES, V58, P2533
  • [7] Druck T, 1997, CANCER RES, V57, P504
  • [8] Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features
    Geradts, J
    Fong, KM
    Zimmerman, PV
    Minna, JD
    [J]. BRITISH JOURNAL OF CANCER, 2000, 82 (06) : 1191 - 1197
  • [9] Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and β-cat genes in squamous cell carcinoma of the head and neck
    González, MV
    Pello, MF
    Ablanedo, P
    Suárez, C
    Alvarez, V
    Coto, E
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1998, 51 (07) : 520 - 524
  • [10] Götte K, 2000, ANTICANCER RES, V20, P1057